Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/173199
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chaccour, Carlos | - |
dc.contributor.author | Casellas, Aina | - |
dc.contributor.author | Blanco-Di Matteo, Andrés | - |
dc.contributor.author | Pineda, Iñigo | - |
dc.contributor.author | Fernández Montero, Alejandro | - |
dc.contributor.author | Ruiz Castillo, Paula | - |
dc.contributor.author | Richardson, Mary-Ann | - |
dc.contributor.author | Rodríguez Mateos, Mariano | - |
dc.contributor.author | Jordán Iborra, Carlota | - |
dc.contributor.author | Brew, Joe | - |
dc.contributor.author | Carmona Torre, Francisco | - |
dc.contributor.author | Giráldez, Miriam | - |
dc.contributor.author | Laso, Ester | - |
dc.contributor.author | Dobaño, Carlota, 1969- | - |
dc.contributor.author | Moncunill, Gemma | - |
dc.contributor.author | Yuste, José R. | - |
dc.contributor.author | Pozo, José L. del | - |
dc.contributor.author | Rabinovich, Regina | - |
dc.contributor.author | Schöning, Verena | - |
dc.contributor.author | Hammann, Felix | - |
dc.contributor.author | Reina, Gabriel | - |
dc.contributor.author | Sadaba, Belen | - |
dc.contributor.author | Fernández Alonso, Miriam | - |
dc.coverage.spatial | Navarra | - |
dc.coverage.temporal | start=2020-07-31; end=2020-10-09 | - |
dc.date.accessioned | 2021-01-18T15:50:33Z | - |
dc.date.available | 2021-01-18T15:50:33Z | - |
dc.date.issued | 2021-01 | - |
dc.identifier.uri | http://hdl.handle.net/2445/173199 | - |
dc.description | Dades primàries associades a l'article publicat a EClinicalMedicine, vol. 32 [https://doi.org./10.1016/j.eclinm.2020.100720] | - |
dc.description.abstract | The trial was conducted in the Pamplona metropolitan area (Navarra, Spain). Patients were enrolled between July 31, 2020 and September 11, 2020 and randomized in a 1:1 ratio to ivermectin (400 mcg/kg) single oral dose or placebo. Assessments on enrollment and at days 4, 7, 14, 21 and 28 post treatment included: general symptoms report, physical examination and adverse events. All patients were asked to complete a daily online diary of symptoms from day 1 to 28 post treatment. On enrollment, as well as on days 7 and 14 blood samples were obtained to assess full blood count, C reactive protein, procalcitonin, ferritin, creatinine phosphokinase, lactic dehydrogenase, troponin T, D dimer, IL-6, and renal function. Viral loads were calculated at enrollment and on days 4, 7, 14 and 21 post treatment based on a nasopharyngeal swab for SARS-CoV-2 PCR (for genes N and E). A semi-quantitative serology for IgG against SARS-CoV-2 was done on samples from all patients on day 21 post-treatment. | ca |
dc.format.mimetype | text/csv | - |
dc.language.iso | eng | ca |
dc.rights | cc-by (c) Chaccour et al., 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Dades - Recerca | - |
dc.subject.classification | Assaigs clínics | cat |
dc.subject.classification | COVID-19 | cat |
dc.subject.classification | Terapèutica | cat |
dc.subject.classification | Pamplona (Navarra) | - |
dc.subject.other | Clinical trials | eng |
dc.subject.other | COVID-19 | eng |
dc.subject.other | Therapeutics | - |
dc.subject.other | Pamplona (Navarra) | - |
dc.title | Data on the effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19 | ca |
dc.type | info:eu-repo/semantics/dataset | ca |
dc.type | info:eu-repo/semantics/other | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | ca |
Appears in Collections: | Dades (ISGlobal) Dades - Recerca |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
saint.csv | Data | 64.64 kB | Unknown | View/Open |
SAINT_data_dictionary.html | Data variables dictionary | 9.69 kB | HTML | View/Open |
saint_dictionary.pdf | Data variables dictionary | 67.84 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License